ClinicalTrials.gg
CompletedNCT03487770Updated Dec 29, 2020

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder

A Phase 3 interventional study of Aripiprazole Oral Solution and Placebo Oral Solution in Autistic Disorder, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing aripiprazole in Autistic Disorder — none open to participants now, none under way, none of them phase 3. Aripiprazole · Autistic Disorder.

Enrollment
4th of 15
111 · median 81
Started
2018
the only one that year
Phase 3
7 of 15
none open now
Registered
15th of 15
by date
Lead sponsor
1 of 15
Otsuka Beijing Research Institute

Among the 15 studies testing aripiprazole in Autistic Disorder, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 3, and was the 15th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

None of the 15 studies testing aripiprazole in Autistic Disorder is open now. The open studies under Autistic Disorder, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing aripiprazole in Autistic Disorder as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, tolerability and the steady-state plasma trough concentration of aripiprazole flexible-dosed in children and adolescents with a diagnosis of Autistic Disorder. Approximately 100 subjects will be randomly assigned at a 1:1 ratio to receive aripiprazole (2 to 15 mg) or placebo treatment for 8 weeks

Read the detailed description

Screening Phase: up to 42 days (consisting of a Screening Visit (V1), a washout period and Interim Screening Visit (V1a) when applicable, and a Baseline Visit (V2). The Screening Phase will serve multiple purposes: to allow for appropriate washout of prohibited medications; to allow for review of screening data; to establish a pre-treatment baseline of key outcome measures.

Treatment Phase: The duration of the treatment is 8 weeks. The purpose of the treatment phase is to evaluate the efficacy, safety, tolerability and steady-state plasma trough concentration of aripiprazole in the treatment of serious behavioral problems in children and adolescents with a diagnosis of Autistic Disorder..

Safety Follow-up Phase: All subjects will be followed up for safety (adverse events) at Day 16 after the last medication via telephone.

03

Conditions studied

  • Autistic Disorder

Browse trials for

Keywords

  • Autistic
  • Aripiprazole Oral Solution
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained from a legally authorized guardianprior to the initiation of any protocol-required procedures.
  2. The subject and/or the designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the Investigator.
  3. The patient meets current diagnostic criteria for Autistic Disorder and also demonstrates behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. In addition, the Childhood Autism Rating Scale (CARS) score is ≥30.
  4. The subject has a Clinical Global Impressions-Severity (CGI-S) score ≥ 4 AND an ABC-I subscale score ≥18 at screening (Visit 1 or Visit 1a) and baseline (V2).
  5. Environmental factors can be consistent throughout the trial period.
  6. The subject is a male or female child or adolescent 6 to 17 years of age (6 ≤ age ≤ 17) at Baseline (V2).

Exclusion criteria

Exclusion Criteria:

  1. Women of (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study.

    Note: WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not [defined as amenorrhea 12 consecutive months; or women on hormone replacement therapy with documented serum follicle stimulating hormone level ≥ 35 mIU/mL].

  2. Women with a positive pregnancy test or who are pregnant or breastfeeding.
  3. The subject has a current diagnosis of psychotic disorder such as bipolar disorder, schizophrenia, or depression.
  4. The subject is currently diagnosed with another disorder on the autism spectrum, including Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Disorder, Rett's Disorder, Childhood Disintegrative Disorder or Fragile-X Syndrome.
  5. The subject has a history of neuroleptic malignant syndrome.
  6. The subject represents a significant risk of committing suicide based on history or routine psychiatric status examination.
  7. The subject has had a seizure in the past year or the electroencephalograph examination is epileptiform discharge at screening.
  8. The subject has a history of severe head trauma or stroke;
  9. The subject has a history or current evidence of any unstable medical conditions (eg. history of congenital heart disease or arrhythmia, or cancer) that, in the judgment of the investigator would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial.
  10. Non-pharmacological therapy (e.g., psychotherapy, behavior modification, and education training, etc.) could not be stable prior to screening and consistent throughout the study, and the subject who needs to use acupuncture and moxibustion, auditory integration, biofeedback and transcranial magnetic stimulation therapy as supplemental replacement therapy in 7 days prior to taking product or during the course of the trial.
  11. The subject is considered treatment resistant to antipsychotics medication, in the opinion of the Investigator, based on lack of therapeutic response to 2 different antipsychotics with reasonable doses after treatment of at least 3 weeks each.
  12. The subjects considered treatment resistant to aripiprazole in the opinion of the investigator based on lack of therapeutic response to an adequate dose and duration of aripiprazole treatment.
  13. The following laboratory test results, vital sign and Electrocardiograph () findings are exclusionary:

    • > 450 msec (male), QTc > 470 msec (female)
    • (below the lower limit)
    • (below the lower limit)
    • Neutrophils (below the lower limit)
    • (SGOT) or ALT (SGPT) (above the upper limit)
    • Creatinine (above the upper limit) In addition, subjects should be excluded if they have any other abnormal laboratory test result, vital sign result or ECG finding that in the investigator's judgment is , in that it would impact the safety of the patient or the interpretation of the study results.
  14. The subject weighs \< 15 kg.
  15. The subject has a known allergy or to aripiprazole or other dihydrocarbostyrils (eg. carteolol, vesnarinone, and cilostazol).
  16. The subject has participated in any clinical trials with an investigational agent within the past month.
  17. Subjects who are likely to require prohibited concomitant therapy during the trial (refer to Section 7 Prohibited and Restricted Therapies).
  18. Subjects who participated in a previous clinical trial of aripiprazole (with the exception of Investigator Sponsored Trials).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Aripiprazole Oral Solution

    1 mg/mL, 2 \~ 15 mg/day (2 \~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals;

    Drug: Aripiprazole Oral Solution

  • Placebo comparator
    Placebo Oral Solution

    2 \~ 15 mg/day (2 \~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals.

    Drug: Placebo Oral Solution

Interventions

  • Aripiprazole 2\~15 mg/day (2\~15 mL/day)

    Also known as: Abilify, Aripiprazole

  • DrugPlacebo Oral Solution

    Placebo 2\~15 mg/day (2\~15 mL/day)

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Changes from Baseline to Week 8 (or endpoint) in the ABC-I score

    The objective of the primary analysis is to compare the efficacy of aripiprazole flexible-dosed (2 \~ 15 mg/day) with placebo in reducing serious behavioral problems, specifically irritability, agitation and self-injurious behavior, in children and adolescents with a diagnosis of Autistic Disorder. The efficacy is assessed by assessed by change from baseline to endpoint on the Irritability Subscale of the ABC (ABC-I).

    Time frame: Baseline and 8 weeks (or endpoint)

Secondary outcomes

  1. Clinician-rated CGI-I score at Week 8 (or endpoint)

    The efficacy is assessed by the clinician-rated CGI-I score at Week 8

    Time frame: Baseline and 8 weeks (or endpoint)

  2. Change in ABC subscale scores from Baseline to Week 8 (or endpoint)

    The efficacy is assessed by changes from Baseline to Week 8 (or endpoint) in Social Withdrawal, Hyperactivity, Stereotypy and Inappropriate Speech Subscale scores of the ABC

    Time frame: Baseline and 8 weeks (or endpoint)

  3. Response Rate at Week 8 (or endpoint) (or endpoint)

    The response is defined as a reduction ≥25% in ABC-I score compared to the baseline, and a CGI-I score of much improved or very much improved) at Week 8 (or endpoint).The efficacy is assessed by response rate at Week 8 (or endpoint).

    Time frame: Baseline and 8 weeks (or endpoint)

07

Study locations

1 site
  • 6th affiliated hospital, Peking University
    Beijing, Beijing 100191, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Apr 2020, 24 months.

Of 15 phase 3 interventional studies under Autistic Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2018
First posted
Apr 4, 2018
StartActual
Apr 9, 2018
Primary completionActual
Apr 21, 2020
CompletionActual
Apr 21, 2020
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03487770
Responsible party
Sponsor
First posted
Apr 4, 2018
Start date
Apr 9, 2018
Primary completion
Apr 21, 2020
Completion
Apr 21, 2020
Last update
Dec 29, 2020

Study contacts

Patyman Juma
study director · Otsuka Beijing Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion